Oncoclínicas Submits Revised Out-of-Court Restructuring Plan Covering R$5.7 Billion in Claims
Bitget2026/10/23 21:55- Oncoclínicas submitted a revised out-of-court restructuring plan on October 23, 2026, covering approximately R$ 5.7 billion in unsecured claims, excluding intercompany claims.
- Payment options include new debt, extended repayment schedules and asset transfers, depending on each creditor’s allocation or election.
- The plan also provides for convertible debentures, payment in company shares and discounts under certain payment options.
- Court approval remains subject to formalized creditor support exceeding the statutory minimum and a 30-day creditor objection period following notice publication.
- Operations continue normally, while obligations incurred after the restructuring filing remain outside the plan and continue to be paid.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Updated version 2-BP reports the highest net profit in at least five years
AstraZeneca (AZN.US) Q3 profit growth surpasses expectations, driven mainly by oncology drugs
AstraZeneca (AZN.US) released its Q3 2026 results on October 30th. At constant exchange rates (CER), total revenue for the quarter increased by 7% year-on-year to $16.209 billions.
BP.US Q3 profits soar to 18-year high: Refining business becomes 'money-printing machine', CEO's reforms encounter strong tailwind
Benefiting from a surge in refining profit margins, BP's quarterly profit jumped to its highest level in 18 years.
Australian Dollar: Bias shifts back to neutral against US Dollar – UOB
Crypto prices
More
